SQZ Candidate Shows Response At Low Dose In HPV16+ Solid Tumor Patient

 

• SQZ Biotechnologies Company 
  SQZ+19.8%+ Free Alerts
   announced that a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 trial. 
• The second and third patients have also been enrolled in the trial. 
• The company has completed the dose-limiting toxicity period for the lowest-dose cohort. 
• The Study Safety Committee has completed its review and recommends that the company enroll patients in the highest dose cohort. 
• The company anticipates initial clinical data from the highest-dose cohort by the fourth quarter of 2023.
• The 61-year-old male patient has a history of metastatic HPV16+ rectal squamous cell carcinoma. The patient had two prior lines of treatment but had not been treated with immune checkpoint inhibitors.
• The patient remains on the study, and the treatment has been well tolerated.
• In December 2022, after two cycles of SQZ-AAC-HPV, a CT scan showed a reduction of the target lesion to meet RECIST 1.1 criteria for a partial response. 
• In February 2023, after four cycles of SQZ-AAC-HPV, a CT scan showed further reduction of the target lesion. 
• In March 2023, after seven cycles of SQZ-AAC-HPV, a CT scan confirmed the complete response.
• SQZ Biotechnologies ended FY22 with a cash balance of $63.7 million, sufficient to runway into 2024.

https://www.benzinga.com/general/biotech/23/03/31474498/sqz-biotechs-cancer-candidate-shows-response-at-low-dose-in-hpv16-solid-tumor-patient